

What is claimed is:

SUB
A1

1. A bone resorption inhibitor which contains leukocyte activating protein factor-showing or leukocyte activating protein factor-derived substances, in an amount effective activity to bone resorption inhibitory.

2. The bone resorption inhibitor according to claim 1, where in the leukocyte activating protein factor has sequences of amino acid number 1 to 151 or 19 to 151.

3. The bone resorption inhibitor according to claim 1 or 2, wherein the leukocyte activating protein factor or leukocyte activating protein factor-derived substances inhibits against osteoclast cell activity.

4. The bone resorption inhibitor according to any of claims 1-3, where in an effective compound shows inhibitory activity of more than 80% at a concentration of 10 µg/ml in the screening methods pit formation, in candidate substances.

5. A screening methods for bone resorption inhibitors derived substances containing leukocyte activating protein factor or leukocyte activating protein factor-derived substances, which are purified from the source of these substances, or which are prepared or synthesized by based on the information of these substances.

6. Use of leukocyte activating protein factor or leukocyte activating protein factor-derived substances in the production of bone resorption inhibitors.

7. A methods for bone resorption inhibiting in animals with bone resorption inhibitors derived substances containing leukocyte activating protein factor or leukocyte activating protein factor-derived substances.

04/16